N/A N=14 Vascular Dysfunction During Physical Inactivity
Aging · Vascular Endothelium · Skeletal Muscle
Primary: Brachial Artery Vascular Function — 5.1; 3.1; 4.4 percent vasodilation
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=19 Blood Flow and Vascular Function in Cystic Fibrosis
Cystic Fibrosis
Primary: Acute Study: Percentage Flow-Mediated Dilation (FMD) — 7.8; 7.7; 7.3; 6.6 percent flow mediated dilation
N/A N=19 Endothelial Function in Lower Extremity Bypass Grafts
Peripheral Arterial Disease
Primary: Change From Baseline in Saphenous Vein Bypass Graft Vasodilation — 5.28 vein bypass graft size increase (%)
N/A N=130 Effect of Vitamin D3 on Vascular Function
Vitamin D Deficiency
Primary: Pulse Wave Velocity for Vascular Stiffness — 29.3; 27.6 m/s
N/A N=51 Passive Mobilization and Vascular Function
Endothelial Dysfunction · Aging · Bed Rest
Primary: Change of Delta Peak Blood Flow During sPLM — 91.9; -24.7 ml/min — p=0.0492
N/A N=202 Dietary Intervention and Vascular Function
Cardiovascular Disease
Primary: Percent Change in Flow Mediated Dilatation (FMD) — -0.39; -0.07; -0.08 post-occlusion diameter change as % — p=0.238
N/A N=99 Effects of Walking and Heating on Vascular Function in Diabetic Patients
Type 2 Diabetes Mellitus · Obesity
Primary: Insulin-stimulated Leg Blood Flow Calculated as Percent Change (t0, t60) — 133.6; 8.92 percentage change
N/A N=30 Role of Flavanols In Cardiovascular Function in Healthy Aging
Aging
Primary: Cutaneous Blood Flow Response to Local Heating of the Skin. — 68; 70 percent change in mean skin blood flow
N/A N=89 Comparing Blood Vessel Endothelial Function in HIV-Infected People and Matched HIV-Uninfected People
HIV Infection
Primary: Endothelial Function (Brachial Artery Reactivity) — 3.98; 3.37 percent dilation — p=0.10
N/A N=33 Vasculaire Compression System Increases Flow Velocity in the Femoral Vein
Venous Thrombosis
Primary: Change in Femoral Venous Peak Flow Velocity Compared to Resting Baseline — 18.9 cm/s — p=<0.0001
Phase 3 N=15 The Role of Mineralocorticoid Receptors in Vascular Function
Apparent Mineralocorticoid Excess (AME)
Primary: Forearm Blood Flow — 1.87; 1.34 ml/100ml of tissue/min
N/A N=23 Long Sleep Duration and Vascular Function
Sleep
Primary: Change From Wake in Central Aortic Pulse Pressure After 11 Hours in Bed — -1.5; 0.5 mm Hg — p=0.36
Phase 2 N=24 Etanercept and Vascular Function in Psoriasis
PSORIASIS
Primary: Vascular Function as Measured by Brachial Artery Flow-mediated Dilation (FMD) — 9.71; 11.15 percentage of brachial artery diameter
Phase 3 N=58 Inflammation and Vascular Function in Atherosclerosis
Atherosclerosis
Primary: Flow-mediated, Endothelium-dependent Vasodilation — 6.8; 8.7 percentage vasodilation
N/A N=20 Sex Differences in Vascular Responses to Exercise
Aging
Primary: Change in FMD in Response to Chronic HIIT — 0.11; 0.57; 0.81; 0.10 % flow mediated dilation
Phase 2 N=31 Red Blood Cell ATP Release and Vascular Function in Humans
Cardiovascular Diseases
Primary: Forearm Blood Flow Responses to Hypoxia After Administration of Intervention — 6.3; 6.2; 2.1; 8.4 mL/min — p=0.97
Phase 3 N=128 Vitamin D and Arterial Function in Patients With Chronic Kidney Disease
Arterial Dysfunction · Chronic Kidney Disease
Primary: Compare the Difference Between the Calcitriol and Cholecalciferol Groups in Conduit Artery Endothelium-dependent Dilation (EDD) in Response to Treatment. — -0.5; 0.3…
N/A N=25 Resveratrol and Vascular Function in CKD
Chronic Kidney Diseases · Endothelial Dysfunction
Primary: % Change of Brachial Artery Flow-mediated Dilation — 1.3; 0.91 %change
Phase 2 N=34 Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
Metabolic Syndrome · Coronary Microvascular Dysfunction
Primary: Absolute Change in Coronary Cross-sectional Area (in mm²) Within the Vericiguat Group as Assessed by Magnetic Resonance Imaging (MRI) — -1.11; 0.40 mm^2 — p=0.0005
Phase 2 N=40 Free Fatty Acids and Vascular Function in Subjects With Diabetes
Type 2 Diabetes Mellitus
Primary: Flow-mediated Dilation After Placebo or Acipimox Treatment Between Healthy Controls and Those With Metabolic Syndrome — 10.65; 11.57; 8.79; 9.52 Flow mediated dilation
Phase 4 N=26 The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation
Heart Failure · Heart Failure With Reduced Ejection Fraction (HFrEF)
Primary: Flow-Mediated Dilation (FMD) — 3.61; 3.66; 4.22; 3.55 % increase from pre-occlusion value
N/A N=125 Non-invasive Computer-Aided Phenotyping of Vasculopathy
Carotid Atherosclerosis · Peripheral Arterial Disease
Primary: Measurement Bias of Calcification Analyzed by vascuCAP™ Non-invasively Relative to Histopathology as Ground Truth. — -0.47; .07 mm2
N/A N=30 Effect of Black Tea on Vascular Function
Vascular Function
Primary: Flow Mediated Dilation, Acute-upon-chronic, Black Tea — 4.24; 4.48; 4.49; 4.87 percentage of flow mediated dilation — p=0.36
N/A N=21 Dietary Nitrates and Vascular Function in Patients With Peripheral Artery Disease
Peripheral Artery Disease
Primary: Change in Vasodilator Capacity — 16.2; 16.4; 16.5; 14.2 ml/100ml tissue/min
N/A N=18 The Effects of Watermelon Juice Supplementation on Postprandial Vascular Endothelial Function
Endothelial Dysfunction
Primary: Endothelial Function — 3.31; 3.53 millimeters
N/A N=47 Influence of Endothelial Function on Central and Peripheral Causes Of Exercise Impairment in Type 2 Diabetes
Type 2 Diabetes
Primary: Percent Change in Circumferential Strain Before and After Exercise at Baseline, After Vitamin C Infusion, and After Exercise Training — -24; -20; -23; -21 percentage of…
N/A N=17 Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women
Cognitive Impairment · Executive Dysfunction · Endothelial Dysfunction
Primary: Changes in Prefrontal Cortex Brain Activation at 6 Months — 90.64; -62.20; 28.07; -79.04 beta-weight
N/A N=30 Flow Mediated Dilation in Response to Black Tea
Vascular Function
Primary: Flow Mediated Dilation — 5.24; 5.02; 6.05; 5.74 percentage of change in diameter — p=0.43
Early Phase 1 N=26 Sex Differences in the Dilatory Response of Compound 21
Sex Differences
Primary: Microvascular AT2R Sensitivity Following Local Control Treatment — 15; 25 percentage of maximal blood flow
Phase 3 N=24 Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Glygocalyx Integrity - Perfused Boundary Region — 0.11; -0.16 Delta micrometers (mcm)